ABL Bio Inc. (KOSDAQ:298380)
South Korea
· Delayed Price · Currency is KRW 140,400
+1,000 (0.72%)
Apr 29, 2026, 12:50 PM KST
ABL Bio Revenue
In the year 2025, ABL Bio had annual revenue of 79.35B KRW with 137.55% growth. ABL Bio had revenue of -370.00 in the quarter ending December 31, 2025, a decrease of -100.00%.
Revenue
79.35B
Revenue Growth
+137.55%
P/S Ratio
98.36
Revenue / Employee
777.94M
Employees
102
Market Cap
7,804.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.35B | 45.95B | 137.55% |
| Dec 31, 2024 | 33.40B | -32.14B | -49.04% |
| Dec 31, 2023 | 65.55B | -1.75B | -2.61% |
| Dec 31, 2022 | 67.30B | 61.97B | 1,162.19% |
| Dec 31, 2021 | 5.33B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,814.00B |
| Celltrion | 4,162.50B |
| ALTEOGEN | 215.86B |
| Samsung Epis Holdings | 1,510.14B |
| Sam Chun Dang Pharm. | 231.81B |
| SK Biopharmaceuticals | 706.74B |
| HLB Co., Ltd. | 84.17B |
| LigaChem Biosciences | 141.55B |